Vertex Pharmaceuticals Incorporated vs TeraWulf Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B), while TeraWulf Inc trades at $20.03 (market cap $9.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13× TeraWulf Inc's market cap. Which is the better fit depends on your goals.
| VRTX | WULF | |
|---|---|---|
Market Cap | $121.95B | $9.35B |
Sector | Health | Technology |
52-Week High | $529.59 | $28.98 |
52-Week Low | $366.54 | $4.76 |
Enterprise Value | $116.69B | $12.03B |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →